CatalYm

CatalYm is a preclinical biotech company developing therapies to address cancer resistance. 

follow the leader arrow growth crowd
Biotech

CatalYm C-suite shake-up sees 4 new faces, 3 departures

CatalYm has tapped four industry leaders to join the immunotherapy biotech, a move that has prompted three other executives to hit the exit.
Gabrielle Masson Sep 15, 2025 10:53am
parachute snow mountains

Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders

Jan 10, 2025 8:30am
photo of a money printer printing out seven rows of 100 bills

CatalYm cashes in on early-stage cancer data with $150M series D

Jul 16, 2024 5:00am